Pratteln, Switzerland, May 20, 2025 – Santhera Pharmaceuticals (SIX: SANN) today announces that its shareholders approved all motions by the Board of Directors at the Annual General Meeting (AGM) held today in Pratteln, Switzerland, with a large majority. Participating shareholders represented a total of 5,073,050 shares or 37.5% of the Company’s share capital. Approval of the 2024 Annual Report and discharge of corporate bodies The shareholders approved the Annual Report, the annual financial statements an ...

Press Release CROSSJECT prepares for the launch of a capital increase with preferential subscription rights of around 5 million euros in preparation for commercial and production activities linked to EUA approval The amount of the proposed transaction (“the Offer”) might be increased to around 5.8 million euros if the extension clause is exercised;Gemmes Venture, the Company's reference shareholder, announced its intention to guarantee the capital increase in cash up to the amount required for its completio ...

Reference is made to the announcement by IDEX Biometrics ASA on 5 May 2025 regarding the results of the exercise of Warrants B. A total of 36,767 Warrants B were exercised, resulting in an aggregate subscription for 36,767 new shares, each Warrant B having an exercise price of NOK 0.15. The share capital increase has duly been registered in the Norwegian Register of Business Enterprises. Following the share capital increase, the company's share capital will be NOK 38,316,309.99, divided into 3,831,630,999 s ...

Reference is made to the announcement by IDEX Biometrics ASA (the "Company") on 12 December 2024 regarding the listing of Warrants A and Warrants B on Oslo Stock Exchange. Warrants B were exercisable between 31 March 2025 and 11 April 2025, and all Warrants B not exercised within such time lapsed without compensation to the holder. A total of 36,767 Warrants B were exercised, resulting in an aggregate subscription for 36,767 new shares (the "New Shares") in the Company, each Warrant B having an exercise pri ...

Core Points - VINCI is conducting a capital increase reserved for its employees in France as part of its savings plan, with the authority delegated by the shareholders' meeting on April 9, 2024 [1][2] - The subscription period for employees to participate in the capital increase will run from May 1 to August 31, 2025 [3] - The issue price for the new shares is set at €97.21, which is 95% of the average opening prices of VINCI shares over the 20 trading days preceding February 6, 2025 [4] - The total number of new shares issued will not exceed 1.5% of the authorized share capital as determined by the shareholders' meeting [5] - The "Castor Relais 2025/2" mutual fund will subscribe to the new shares, which will be admitted to trading on Euronext Paris after their creation [6]